Evicenter
MarkdownMedical informationP&T meetings
Envudeucitinib (ESK-001)

Moderate-to-severe plaque psoriasis

Also known as FTP-637
Manufacturer
Alumis
Launch
Not announced
Last updated
277 sources

Section 1 of 6

Terms and abbreviations

1 evidence topic · 0 sources

AbbreviationTerm
2Q26Second quarter of 2026
4QFourth quarter
A-005Alumis development code for a central nervous system penetrant allosteric TYK2 inhibitor
AADAmerican Academy of Dermatology
AAD-NPFAmerican Academy of Dermatology and National Psoriasis Foundation (joint guidelines)
AAPCAverage annual percent change
ACDAdjusted cost difference
ADAtopic dermatitis
ADAAdalimumab
ADRsAdverse drug reactions
AE, AEsAdverse event; adverse effect
AHFSAmerican Hospital Formulary Service
aHR, aHRsAdjusted hazard ratio
aIRRAdjusted incidence rate ratio
ALPAlkaline phosphatase
ALTAlanine aminotransferase
ANOVAAnalysis of variance
anti-HBcAntibody to hepatitis B core antigen
anti-HBsAntibody to hepatitis B surface antigen
ANZCTRAustralian New Zealand Clinical Trials Registry
aORAdjusted odds ratio
APACAsia-Pacific
APIActive pharmaceutical ingredient; application programming interface
ASIRAge-standardized incidence rate
ASPAverage sales price
ASR, ASRsAge-standardized rate
ASTAspartate aminotransferase
ATMAt-the-market (equity offering)
ATPAdenosine triphosphate
AUCArea under the concentration-time curve
AUC(0-τ), AUC0-τ, AUC0–tau, AUCtauArea under the concentration-time curve over the dosing interval
AUC(INF), AUC0–infArea under the concentration-time curve from time zero extrapolated to infinite time
AUC0-τ,ssArea under the concentration-time curve for the dosing interval at steady state
AUC0–t, AUCtArea under the concentration-time curve from time zero to the last measurable concentration
BADBritish Association of Dermatologists
BIDTwice daily
BIWTwice weekly
BMIBody mass index
BMSBristol Myers Squibb
BMT-153261Code for the active metabolite of deucravacitinib
BPBlood pressure
BSABody surface area
BWAUC, BWAUC0-τBody weight normalized area under the concentration-time curve
BWCmaxBody weight normalized maximum plasma concentration
CCL19C-C motif chemokine ligand 19
CCR7C-C motif chemokine receptor 7
CESCarboxylesterase
CI, CIsConfidence interval
CKDChronic kidney disease
CL/FApparent clearance
CLrRenal clearance of unchanged drug from the plasma
CmaxMaximum observed plasma concentration
Cmax,ssMaximum plasma concentration at steady state
CMSCenters for Medicare & Medicaid Services
CNSCentral nervous system
COPDChronic obstructive pulmonary disease
COVID-19, COVIDCoronavirus disease 2019
CPKCreatine phosphokinase
CPR, CPRsCost per response
CPTCurrent Procedural Terminology
CrClCreatinine clearance
CrICredible interval
CROClinical research organization
CRUClinical research unit
CtroughTrough plasma concentration (concentration immediately before the next dose)
CV, CV%Cardiovascular; coefficient of variation
CXCL1, CXCL2, CXCL3, CXCL5, CXCL8, CXCL10C-X-C motif chemokine ligand 1, 2, 3, 5, 8, and 10
CYCalendar year
CYP, CYP450, P450Cytochrome P450
DDIDrug-drug interaction
DEUDeucravacitinib
DLQIDermatology Life Quality Index
DLQI 0/1, DLQI-0/1, DLQI0/1Dermatology Life Quality Index score of 0 or 1
DSHSDepartment of State Health Services (Texas)
E-RExposure-response
EAIR, EAIRsExposure-adjusted incidence rate
ECG, ECGsElectrocardiogram
eCRFElectronic case report form
EDErectile dysfunction
EEExpert elicitation
EEAEuropean Economic Area
EFEfficiency frontier
eGFREstimated glomerular filtration rate
EHRElectronic health record
EMAEuropean Medicines Agency
envuEnvudeucitinib (manufacturer shorthand)
EQ-5D, EQ-5D-3L, EQ-5D-5LEuroQol 5-Dimension questionnaire (3-level and 5-level versions)
EQ-VASEuroQol visual analogue scale
EREmergency room
ERAP1Endoplasmic reticulum aminopeptidase 1
ESK-001, ESK001, ESK 001Alumis development code for envudeucitinib
EUEuropean Union
EU5France, Germany, Spain, the U.K., and Italy
EudraCTEuropean Union Drug Regulating Authorities Clinical Trials Database
FDAU.S. Food and Drug Administration
FDLQIFamily Dermatology Life Quality Index
%FePercentage of unchanged drug excreted
FEFood effect
FSHFollicle-stimulating hormone
FSSFederal Supply Schedule
FTP-637FronThera development code for envudeucitinib
GBDGlobal Burden of Disease (study)
GGTGamma glutamyl transferase
GIGastrointestinal
GQGlobal question
H2Histamine-2 (receptor)
HBsAgHepatitis B surface antigen
HBVHepatitis B virus
HCAIDepartment of Health Care Access and Information (California)
HCPCSHealthcare Common Procedure Coding System
HCProHUMIRA Complete Pro (online prescription management system)
HCRUHealthcare resource utilization
HCVHepatitis C virus
HEDISHealthcare Effectiveness Data and Information Set
HERC5HECT and RLD domain containing E3 ubiquitin protein ligase 5
hERGHuman ether-a-go-go-related gene
HIV, HIV-1, HIV-2Human immunodeficiency virus (types 1 and 2)
HLA-CHuman leukocyte antigen C
HMOHealth maintenance organization
HRHazard ratio; heart rate; hour (in a product description)
HRQOL, HRQoL, HrQOLHealth-related quality of life
HWBHuman whole blood
IBDInflammatory bowel disease
IC5050% inhibitory concentration
IC9090% inhibitory concentration
ICC, ICCsIntraclass correlation coefficient
ICD, ICD-10, ICD-10-CM, ICD-9-CMInternational Classification of Diseases (10th revision; 10th and 9th revisions, Clinical Modification)
ICERInstitute for Clinical and Economic Review; incremental cost-effectiveness ratio
ICFInformed consent form
ICHInternational Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use
IDIdentifier
IFI27Interferon alpha inducible protein 27
IFIH1Interferon induced with helicase C domain 1
IFIT1Interferon induced protein with tetratricopeptide repeats 1
IFN, IFNsInterferon
IFNGSInterferon gene signature
IFNαInterferon alpha
IFNγ, IFNGInterferon gamma
IGAInvestigator’s Global Assessment
IGRAInterferon-gamma release assay
ILInterleukin
IL12BInterleukin 12B (gene)
IL23RInterleukin 23 receptor (gene)
IL4I1Interleukin 4 induced 1
IMIntramuscular
INJInjection (in a product description)
INNInternational Nonproprietary Name
IPCInternational Psoriasis Council
IPDImportant protocol deviations
IQRInterquartile range
IRASIntegrated Research Application System
IRR, IRRsIncidence rate ratio
ITTIntent-to-treat (intention-to-treat)
IUDIntrauterine device
IVIntravenous
JAK, JAK1, JAK2, JAK3Janus kinase (1, 2, 3)
JAKiJanus kinase inhibitors
JH1JAK homology 1 (catalytic kinase domain)
JH2JAK homology 2 (pseudokinase domain)
LCE3Late cornified envelope 3
LOCFLast observation carried forward
LSLeast squares
LSMsLeast squares means
LTELong-term extension
MACEMajor adverse cardiovascular events
MADMultiple ascending dose
%Max_AUCW16Percent maximum area under the response curve through week 16
mBOCFModified baseline observation carried forward
MCDsMean cost differences
MDMultiple-dose (study)
MFPsMaximum fair prices
MHCMajor histocompatibility complex
MIMyocardial infarction
MIPSMerit-based Incentive Payment System
mITTModified intent-to-treat
MMFMycophenolate mofetil
MMRMMixed model with repeated measures
mNRIModified non-responder imputation
MRMendelian randomization
MRAUCMetabolite to parent ratio based on area under the concentration-time curve
MRCmaxMetabolite to parent ratio based on maximum plasma concentration
mRNAMessenger ribonucleic acid
MSMultiple sclerosis
MSPPModerate-to-severe plaque psoriasis
MTXMethotrexate
NAFLDNonalcoholic fatty liver disease
NB-UVBNarrowband ultraviolet B
NCQANational Committee for Quality Assurance
NDANew Drug Application
NDC, NDCs, NDC11National Drug Code (11-digit format)
NF-kappa BNuclear factor kappa B
NHANESNational Health and Nutrition Examination Survey
NHISNational Health Interview Survey
NMSCNonmelanoma skin cancer
NNTNumber needed to treat
NPFNational Psoriasis Foundation
NRINon-responder imputation
NRSNumeric Rating Scale
NRWNorth Rhine-Westphalia (in an address)
NYSENew York Stock Exchange
OLEOpen-label extension
OROdds ratio
OSAObstructive sleep apnea
P-gpP-glycoprotein
P-SIMPsoriasis Symptoms and Impacts Measure
PA, PAsPrior authorization
PASIPsoriasis Area and Severity Index
PASI 50, PASI 75, PASI 90, PASI 100 (PASI-50, PASI-75, PASI75, PASI-90, PASI90, PASI-100)Improvement from baseline in the Psoriasis Area and Severity Index of at least 50%, 75%, 90%, or 100%
PCTPatent Cooperation Treaty
PDPharmacodynamics
PDE4Phosphodiesterase 4
PDIPsoriasis Disability Index
PDUFAPrescription Drug User Fee Act
PESTPsoriasis Epidemiology Screening Tool
PFISPatient Family Impact Score
PFSPrefilled syringe (in a product description)
PGAPhysician’s Global Assessment
Ph1, Ph2Phase 1, phase 2
PHQ-2Patient Health Questionnaire-2
PIPrincipal investigator
PKPharmacokinetics
PMPMPer member per month
PPPer-protocol
PPIsProton pump inhibitors
PPOPreferred provider organization
PPPMPer patient per month
PPPYPer patient per year
PRPR interval of the electrocardiogram (onset of the P wave to onset of the QRS complex)
PsPlaque psoriasis
PsAPsoriatic arthritis
PsO, PSOPsoriasis; plaque psoriasis
PsoRAPsoriasis Registry Austria
PSQIPittsburgh Sleep Quality Index
PSSDPsoriasis Symptoms and Signs Diary
pSTAT, pSTAT1Phosphorylated signal transducer and activator of transcription (1)
PTPreferred term
PUVAPsoralen plus ultraviolet A
PYPatient-years; participant-years
Q1First quarter
Q12Every 12 hours
Q2WEvery 2 weeks
Q3Third quarter
QALY, QALYsQuality-adjusted life year
QCDRQualified Clinical Data Registry
QD, q.d.Once daily
QoL, QOLQuality of life
QRSQRS complex of the electrocardiogram (ventricular depolarization)
QTQT interval of the electrocardiogram (onset of the QRS complex to end of the T wave)
QTcQT interval corrected for heart rate
QTcFQT interval corrected using Fridericia’s method
∆∆QTcFChange from baseline in placebo-adjusted QT interval corrected using Fridericia’s method
RARheumatoid arthritis
RAC, RacAccumulation ratio
RCTsRandomized controlled trials
RECResearch Ethics Committee
REMSRisk Evaluation and Mitigation Strategy
RNARibonucleic acid
RNA-seqRibonucleic acid sequencing
RNF113Ring finger protein 113
ROWRest of world
RR, RRsRelative risk (risk ratio)
RSAD2Radical S-adenosyl methionine domain containing 2
RWPRandomized withdrawal period
RZBRisankizumab
SASouth Australia
SADSingle ascending dose
SAE, SAEsSerious adverse event
SARS-CoV-2Severe acute respiratory syndrome coronavirus 2
SCSubcutaneous
SDStandard deviation; sleep disturbance
SIGLEC1Sialic acid binding Ig like lectin 1
SIRStandard incidence rate
SLESystemic lupus erythematosus
SMCSafety monitoring committee
SMDStandardized mean difference
SMRStandardized mortality ratio
SNPSingle nucleotide polymorphism
SOCSystem organ class
sPGAStatic Physician’s Global Assessment
sPGA 0/1, sPGA-0/1Static Physician’s Global Assessment score of 0 (clear) or 1 (almost clear)
ss-PGA, ssPGAScalp-specific Physician’s Global Assessment
ss-PGA-0/1Scalp-specific Physician’s Global Assessment score of 0 (clear) or 1 (almost clear)
STAT, STAT1, STAT3, STAT4Signal transducer and activator of transcription (1, 3, 4)
StrepStreptococcus
SUCRASurface under the cumulative ranking curve
t1/2, t½, t½λzElimination half-life
t1/2,ssTerminal elimination half-life at steady state
TABTablet (in a product description)
TAK-279Takeda development code for zasocitinib
TBTuberculosis
TEAE, TEAEsTreatment-emergent adverse event
Th1T helper 1
Th17T helper 17
TmaxTime of maximum plasma concentration
Tmax,ssTime to reach maximum plasma concentration at steady state
TNF, TNFα, TNF-alphaTumor necrosis factor (alpha)
TNIP1TNFAIP3 interacting protein 1
TPOThrombopoietin
TSETokyo Stock Exchange
TYK2, TYK-2Tyrosine kinase 2
TYK2iTYK2 inhibition; TYK2 inhibitors
U.K., UKUnited Kingdom
U.S., USUnited States
UGTUridine glucuronyl transferase
ULNUpper limit of normal
USAUnited States of America
USANUnited States Adopted Name
USDU.S. dollars
UVUltraviolet; uveitis
UVB, UV-BUltraviolet B
Vd/FApparent volume of distribution
VRSVisual Rating Scale
Vss/FApparent steady-state volume of distribution
Vz/FApparent volume of distribution during the terminal phase
WAC, WACsWholesale acquisition cost
WHOWorld Health Organization
WHO-DDWorld Health Organization Drug Dictionary
WMDWeighted mean difference
WOCBPWomen of childbearing potential
WPAIWork Productivity and Activity Impairment (instrument)
WPLWork productivity loss
XRExtended release